OptiBiotix has carried out a consumer study in users of the company's probiotic, Lactobacillus plantarum (LPLDL) containing formulation, CholBiome. The findings of this consumer study support the human clinical study of LPLDL, published 18 January 2022, which demonstrated the statistically significant effect of LPLDL on reducing total cholesterol, LDL-cholesterol and APO-B. The survey found 96% of consumers reported reductions in total cholesterol (17% reported a >30% reduction) and 88% reported ....
